Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria
Open Access
- 20 April 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Neglected Tropical Diseases
- Vol. 12 (4), e0006440
- https://doi.org/10.1371/journal.pntd.0006440
Abstract
The 8-aminoquinoline antimalarials, the only drugs which prevent relapse of vivax and ovale malaria (radical cure), cause dose-dependent oxidant haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients with P. vivax conferred by G6PD deficiency. If tafenoquine is deployed for radical cure, primaquine will still be needed to obtain high population coverage. Better radical cure antimalarial regimens are needed. More than half of the malaria outside of Sub-Saharan Africa is caused by the parasite Plasmodium vivax which is characterised by multiple relapses of malaria from parasites which persist in the liver. The only drugs which prevent these relapses (radical cure) are the 8-aminoquinolines primaquine and tafenoquine, and they both cause haemolytic anaemia in G6PD deficiency, the most common enzymopathy of man. Neither can currently be prescribed in pregnancy or lactation. Tafenoquine is given as a single dose regimen and is a significant advance over primaquine (recommended as a 14 day regimen). However, a greater number of individuals, mostly females, will be ineligible for tafenoquine treatment due to a tighter restriction on the minimum G6PD enzyme activity considered safe for use of the drug. Using enzyme activity data from over 5000 individuals, we estimate the proportions ineligible due to G6PD deficiency as a function of the deficient allele prevalence. Adding this to simple estimates of pregnancy and lactation, we estimate the proportions of populations who cannot receive either tafenoquine or primaquine radical cure. For the elimination of vivax malaria in areas with a high prevalence of G6PD deficiency, then if tafenoquine is deployed primaquine will still be needed, so better regimens should be developed.Keywords
Funding Information
- Wellcome Trust (089179/Z/09/Z)
This publication has 42 references indexed in Scilit:
- Spatial distribution of G6PD deficiency variants across malaria-endemic regionsMalaria Journal, 2013
- G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD testsMalaria Journal, 2013
- The metabolism of primaquine to its active metabolite is dependent on CYP 2D6Malaria Journal, 2013
- G6PD deficiency in Plasmodium falciparum and Plasmodium vivax malaria-infected Cambodian patientsMalaria Journal, 2013
- G6PD Deficiency Prevalence and Estimates of Affected Populations in Malaria Endemic Countries: A Geostatistical Model-Based MapPLoS Medicine, 2012
- Relapses Contribute Significantly to the Risk of Plasmodium vivax Infection and Disease in Papua New Guinean Children 1–5 Years of AgeThe Journal of Infectious Diseases, 2012
- Primaquine radical cure of Plasmodium vivax: a critical review of the literatureMalaria Journal, 2012
- Performance of the CareStart™ G6PD Deficiency Screening Test, a Point-of-Care Diagnostic for Primaquine Therapy ScreeningPLOS ONE, 2011
- Determinants of relapse periodicity in Plasmodium vivax malariaMalaria Journal, 2011
- The Impact of Phenotypic and Genotypic G6PD Deficiency on Risk of Plasmodium vivax Infection: A Case-Control Study amongst Afghan Refugees in PakistanPLoS Medicine, 2010